3 резултати
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the 35 U.S.C. .sctn.371 national stage of PCT application PCT/JP2005/007354, filed Apr. 11, 2005, which claims priority to Japanese patent application No. 116725/2004, filed Apr. 12, 2004. The contents of these applications are incorporated
TECHNICAL FIELD
The present invention relates to treatment of cancer. More specifically the invention relates to methods of treating cancer by administering antibodies directed to .alpha.2.beta.1 integrin.
BACKGROUND OF THE INVENTION
The integrin .alpha.2.beta.1 (Very late antigen 2; VLA-2) is
FIELD OF THE INVENTION
This invention is related to the use of leukemia inhibitory factor (LIF) and other agonists of the LIF receptor, in the regulation of inflammation and pain.
BACKGROUND
Leukemia inhibitory factor (LIF) belongs to the neuropoietic cytokine family, which also includes ciliary